Member Info for JohnHenry

RP2020 have you actually considered the rate of flow of this 4.7% Helium.

Apologise missed a paragraph in the RNS

Predator Oil & Gas Holdings PLC Operations Update and 2024 Forward Work Programme

Why the company are pushing ahead with MOU 5 well rather than MOU3 SE and MOU3 NE

If a simple test does in fact show equivalence then the delay should be fairly minimal

Imho if MET B drops below $200 again for a number of weeks/months Ben will mothball the plant until a more positive visibility on Met coal price.

Met B $215

The near halving of the share price is not imho due to the fundamentals of the company but a large seller more than likely the same one thats been dripping stock into the markets for months triggering a massive amount of stops.

Today could be the capitulation reversal day

Rollover

Imho once a deal is concluded on XF73 Nasal, the JV wont hang around with phase 3 they will be right on it.

FDA /EMA. Clinicians will be pushing this study to be started and competed ASAP

XF73 is a product that was needed yesterday.

They need a Train every 4 days.

Completely agree, the train service to Bens Creek is so so unreliable.

So unreliable to the fact your really cant stamp any meaningful production and delivery numbers.

Its pretty much all over the place.

On full production 70k a month BEN are breakeven @ $200 50K breakeven @ $205

At $225 MetB 70K gives $ 1.75M £1.38M. 50k gives $1M £800K profit per month

Note the huge uplift in profit @ full production.

The issue with BEN is that there are always issues, so you never know whats actually going on.

Trains how many were delivered in Jan zero 1,2 3, 6 ?

IMHO the M3 update has done the damage

A change in the dose formulation will no doubt lead to a renewed phase 2 study.

How much funding will DEST be required to contribute to this new phase 2.

Phase 3 now looks at least 2 years away

Aimho

Dr Bill Love, Chief Scientific Officer of Destiny Pharma said: "I would like to thank NIAID for their support and collaboration throughout the preclinical safety study in XF-73 Dermal and I am delighted to announce this positive dataset.

Noix Bill Love commented that he was pleased to share the new dataset.

There was no dataset in the RNS.

Tatty for DEST thats high volume ( free float is low)

All the large delayed trades are sells but appearing in the buy column.

Poster on another site said the company should have referenced the data from the July RNS.

I tend to agree.

Kipper1960 once the traders are out imho the market will begin to realise the massive value being created here.

There is no doubt Dermal will eventually go into Phase 3

The XF platform is massive.